Available Clinical Trials Update - The Alliance Alternate Trial, from Gary Unzeitig MD
I’m going to write you periodically about ongoing clinical trials , trials soon to come, and other research related issues. I’d say that the ALTERNATE trial is currently my favorite. Eligible patients have palpable tumors > 2cm ER + >70%, Her-2 negative.
There is a 3 arm randomization, as shown, to one of 3 neoadjuvant endocrine arms. Arm 1 is Arimidex (A). Arm 2 is Faslodex (F). Arm 3 is A+F. Repeat cores/blood are due at week 4. Ki67 must be 10 or less to stay on their assigned arm (patients find this very reassuring) to complete 6mos.
I know the schema looks complicated but in reality, its very straightforward and very few patients are switched to chemotherapy.